According to Art. 100t of the Law on Public Offering of Securities, Sopharma AD has announced a significant increase in sales for June 2025. The company reported a 49% rise in total sales compared to the same month last year. This includes a 5% increase in domestic sales and a notable 92% surge in export sales, attributed to the uneven recovery in key export markets.
From the start of 2025, Sopharma AD achieved a 9% overall increase in sales. This figure encompasses a 3% decline in domestic sales alongside an 18% growth in export sales.
